Mega Genomics Limited (HKG:6667)

Market Cap	1.63B -24.6%
Revenue (ttm)	275.03M +50.5%
Net Income	30.07M -40.0%
EPS	0.15 -37.0%
Shares Out	224.30M
PE Ratio	47.80
Forward PE	n/a
Dividend	0.17 (2.37%)
Ex-Dividend Date	n/a

Volume	2,800
Average Volume	3,670
Open	7.52
Previous Close	7.31
Day's Range	7.28 - 7.52
52-Week Range	6.19 - 7.53
Beta	0.81
RSI	51.15
Earnings Date	Mar 31, 2026

About Mega Genomics

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 203
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6667

Financial Performance

In 2025, Mega Genomics's revenue was 247.15 million, an increase of 50.49% compared to the previous year's 164.23 million. Earnings were 27.02 million, a decrease of -40.01%.

Financial numbers in CNY